Back to search results

Olpasiran for Cardiovascular Disease and Lipoprotein(a) Reduction

This study is testing a drug called olpasiran to see if it can reduce the amount of non-calcified plaque (NCP) in your arteries, compared to a placebo (an inactive substance). NCP is a type of buildup in blood vessels linked to heart disease. You may be able to join if you are 35 to 80 years old, have high levels of Lp(a) (a type of fat in the blood), and have existing coronary artery disease or a history of heart attack or a procedure to open blocked arteries. The main goal is to measure changes in NCP volume over 72 weeks using a special heart scan called Coronary Computed Tomography Angiography (CCTA). The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 406 participants. It compares olpasiran to a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured from baseline to Week 72.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07293260

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Recruiting
PHASE3Ages 35–80InterventionalTreatment
Amgen
~406 participants
Updated 2026-04-16 on ClinicalTrials.gov
What's tested:OlpasiranPlacebo

At a glance

Recruiting sites
40 of 40 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in NCP Volume from Baseline to Week 72
Measured over Baseline to Week 72

Conditions

Cardiovascular Disease

Explore related trials

AtherosclerosisCardiovascular Disorder

Where it's being run

40 sites across 28 states
France4
Germany4
Italy4
Queensland2
Hunan2
Denmark2
Connecticut1
Florida1

Study leadership

  • MD · STUDY_DIRECTOR · Amgen

Who to contact

Amgen Call Center
[email protected]
866-572-6436
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 35 to ≤ 80 years.
Lp(a) ≥ 200 nmol/L during screening.
Angiographic evidence of coronary artery disease in at least one major epicardial vessel on screening CCTA.
History of myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or coronary revascularization by percutaneous coronary intervention.

Exclusion

History of coronary artery bypass graft (CABG).
Moderate to severe renal dysfunction.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or total bilirubin (TBL) \> 2 x ULN during screening.
History of hemorrhagic stroke.
History of major bleeding disorder.
Planned cardiac surgery or arterial revascularization.
Severe heart failure.
Current, recent, or planned lipoprotein apheresis.
Previously received ribonucleic acid therapy specifically targeting Lp(a).

What this trial measures

  • Change in NCP Volume from Baseline to Week 72Baseline to Week 72